Nutra Pharma Expands Licensing Agreement to Include Environmental Testing for Nontuberculous Mycobacterium
December 27 2007 - 9:00AM
Business Wire
Nutra Pharma Corp. (OTCBB:NPHC), a biotechnology company that is
developing drugs for HIV and Multiple Sclerosis (MS), has today
announced that it has expanded its licensing agreement with
NanoLogix, Inc., (Pink Sheets: NNLX) to include intellectual
property for the use of testing the environment for NonTuberculous
Mycobacterium (NTM). �NTM infections are becoming a major concern
for hospitals and medical clinics around the world,� explained Rik
J. Deitsch, Chairman and CEO of Nutra Pharma Corporation.
�Combining our newly licensed intellectual property with our
current test kit technology will allow our subsidiary, Designer
Diagnostics, to attempt to successfully launch a cost-effective
solution to help identify the environmental sources of NTM
infections,� he added. NonTuberculous Mycobacterium, also known as
atypical Tuberculosis (Atypical TB) or Mycobacterium other than
Tuberculosis (MOTT), is a bacteria that is found in water,
including hot tubs and showers, some domestic and wild animals, and
soil. One of the most common forms of NTM infections found in
humans is Mycobacterium avium complex (MAC). This is a primary
cause of respiratory disease in humans and is a leading cause of
death in HIV/AIDS patients. �Expanding this licensing agreement to
include environmental testing is a natural progression of our
relationship with Nutra Pharma and our belief in its ability to
successfully bring these kits to market,� commented Bret Barnhizer,
President and CEO of NanoLogix, Inc. �In addition to helping detect
NTM in patients, Nutra Pharma will now be able to test for NTM in
the environment to help prevent others from becoming infected,� he
concluded. Nutra Pharma�s wholly-owned medical devices subsidiary,
Designer Diagnostics, is currently planning to undergo third party
validation for its NTM diagnostic test kits at leading Tuberculosis
research institute, National Jewish Medical and Research Center, in
Denver, Colorado. The Company plans to apply for FDA approval upon
successful completion of this clinical trial. Recently,
distinguished NTM research scientist, Dr. Rahul Narang, used the
Designer Diagnostics test kits to test soil and water samples
collected from the environment of patients with NTM infections.
This was the first time the technique was used in India and the
findings were presented in November at the 38th Union World
Conference on Lung Health in Cape Town, South Africa. About Nutra
Pharma Corp. Nutra Pharma Corp. is a biopharmaceutical company
specializing in the acquisition, licensing and commercialization of
pharmaceutical products and technologies for the management of
neurological disorders, cancer, autoimmune and infectious diseases.
Nutra Pharma Corp. through its subsidiaries carries out basic drug
discovery research and clinical development and also seeks
strategic licensing partnerships to reduce the risks associated
with the drug development process. The Company's holding,
ReceptoPharm, Inc, is developing these technologies for the
production of drugs for HIV and Multiple Sclerosis ("MS"). The
Company's subsidiary, Designer Diagnostics, is engaged in the
research and development of diagnostic test kits designed to be
used for the rapid identification of infectious diseases such as
Tuberculosis (TB) and Mycobacterium avium-intracellulare (MAI).
Nutra Pharma continues to identify and acquire intellectual
property and companies in the biotechnology arena.
http://www.NutraPharma.com http://www.DesignerDiagnostics.com SEC
Disclaimer This press release contains forward-looking statements.
The words or phrases "would be," "will allow," "intends to," "will
likely result," "are expected to," "will continue," "is
anticipated," "estimate," "project," or similar expressions are
intended to identify "forward-looking statements." Actual results
could differ materially from those projected in Nutra Pharma's
("the Company") business plan. The Company's business is subject to
various risks, which are discussed in the Company's filings with
the Securities and Exchange Commission ("SEC"). The expanded
licensing agreement with NanoLogix, Inc., to include environmental
testing should not be construed as an indication in any way
whatsoever of the value of the Company or its common stock. The
Company's filings may be accessed at the SEC's Edgar system at
www.sec.gov. Statements made herein are as of the date of this
press release and should not be relied upon as of any subsequent
date. The Company cautions readers not to place reliance on such
statements. Unless otherwise required by applicable law, we do not
undertake, and we specifically disclaim any obligation, to update
any forward-looking statements to reflect occurrences,
developments, unanticipated events or circumstances after the date
of such statement.
NanoLogix (CE) (USOTC:NNLX)
Historical Stock Chart
From Jun 2024 to Jul 2024
NanoLogix (CE) (USOTC:NNLX)
Historical Stock Chart
From Jul 2023 to Jul 2024